UZEDY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Uzedy, and when can generic versions of Uzedy launch?
Uzedy is a drug marketed by Teva and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and nine patent family members in thirty-five countries.
The generic ingredient in UZEDY is risperidone. There are thirty drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the risperidone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Uzedy
A generic version of UZEDY was approved as risperidone by RISING on October 8th, 2008.
US Patents and Regulatory Information for UZEDY
UZEDY is protected by nine US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-005 | Apr 28, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-004 | Apr 28, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-006 | Apr 28, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-006 | Apr 28, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-006 | Apr 28, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-007 | Apr 28, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for UZEDY
See the table below for patents covering UZEDY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2005206143 | Long-term delivery formulations and methods of use thereof | ⤷ Start Trial |
| Australia | 2006269927 | Drug-containing implants and methods of use thereof | ⤷ Start Trial |
| Canada | 2553254 | PREPARATIONS A LIBERATION A LONG TERME ET PROCEDES D'UTLISATION DE CELLES-CI (LONG-TERM DELIVERY FORMULATIONS AND METHODS OF USE THEREOF) | ⤷ Start Trial |
| Canada | 2614601 | IMPLANTS CONTENANT UN MEDICAMENT ET LEUR PROCEDE D'UTILISATION (DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF) | ⤷ Start Trial |
| China | 101287423 | Drug-containing implants and methods of use thereof | ⤷ Start Trial |
| China | 103637977 | Drug-containing implants and methods of use thereof | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for UZEDY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0196132 | 94C0008 | Belgium | ⤷ Start Trial | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch